stock
Specialty Chemical Stock Recovers From Losses After Reporting Strong Q4 Profit Growth
Sudarshan Chemical Industries Ltd6 hours ago
Loading market data...
Pfizer India posted FY26 revenue of ₹2,519.65 crore and net profit of ₹722.43 crore while announcing a ₹75 final dividend for shareholders. Strong cash flow generation and stable pharmaceutical demand supported performance despite exceptional charges.
Reviewed and Rewrite by
Rudransh Sangwan
Pfizer India reported a strong financial performance for FY26 with revenue growth, healthy operational cash generation, and a major dividend announcement for shareholders. The pharmaceutical giant announced a final dividend of ₹75 per share for the financial year ended March 31, 2026, reflecting continued focus on shareholder returns despite exceptional cost pressures during the year.
The company’s audited results for FY26 showed stable growth in operations as India’s pharmaceutical sector continued benefiting from rising healthcare demand, premium branded medicines, and expanding chronic therapy markets.
Pfizer India reported revenue from operations of ₹2,519.65 crore for FY26 compared to ₹2,281.35 crore in FY25, reflecting steady year-on-year growth.
Meanwhile, total income rose to ₹2,707.60 crore, supported by higher operational revenue and growth in other income streams.
| Metric | FY26 | FY25 |
|---|---|---|
| Revenue from Operations | ₹2,519.65 crore | ₹2,281.35 crore |
| Total Income | ₹2,707.60 crore | ₹2,453.60 crore |
| Net Profit | ₹722.43 crore | ₹767.60 crore |
| Profit Before Tax | ₹975.67 crore | ₹1,016.09 crore |
| Total Expenses | ₹1,682.77 crore | ₹1,610.32 crore |
| EPS | ₹157.92 | ₹167.79 |
| Operating Cash Flow | ₹967.57 crore | ₹659.75 crore |
Although net profit declined slightly year-on-year, profitability remained strong considering the exceptional charges recorded during FY26.
Pfizer India’s Board recommended a final dividend of ₹75 per equity share of face value ₹10 each for FY26.
| Particulars | Details |
|---|---|
| Final Dividend | ₹75 per share |
| Dividend Percentage | 750% |
| Total Dividend Payout | ₹343.11 crore |
| Record Date | July 17, 2026 |
| Payment Date | On or after August 4, 2026 |
The dividend remains subject to shareholder approval at the company’s upcoming Annual General Meeting (AGM).
The large payout highlights Pfizer India’s strong balance sheet, healthy cash generation, and shareholder-friendly capital allocation strategy.
For the March quarter, Pfizer India reported healthy operational performance despite industry-wide cost pressures.
| Metric | Q4 FY26 | Q4 FY25 |
|---|---|---|
| Revenue from Operations | ₹629.23 crore | ₹591.91 crore |
| Net Profit | ₹199.82 crore | ₹330.94 crore |
| Total Income | ₹669.95 crore | ₹636.49 crore |
| Profit Before Tax | ₹259.78 crore | ₹252.99 crore |
Revenue growth remained positive during the quarter, although profitability was impacted by exceptional expenses and operational adjustments.
Pfizer India reported exceptional charges worth ₹49.16 crore during FY26.
The charges primarily included:
The company had entered into an agreement involving brands such as:
In comparison, FY25 included exceptional gains from property-related transactions, which had boosted profitability during the previous financial year.
One of the biggest positives in Pfizer India’s FY26 results was the strong operational cash flow generation.
Net cash generated from operating activities rose sharply to ₹967.57 crore during FY26.
| Metric | FY26 |
|---|---|
| Total Assets | ₹4,921.88 crore |
| Total Equity | ₹4,202.90 crore |
| Cash & Cash Equivalents | ₹102.66 crore |
The company also utilized significant cash flows toward:
Despite these outflows, Pfizer India continues maintaining a very strong balance sheet with low leverage exposure.
The broader pharmaceutical sector in India continues benefiting from multiple long-term structural trends, including:
Defensive pharmaceutical businesses often attract investors during periods of macroeconomic uncertainty because of:
Pfizer India remains one of the well-recognized multinational pharmaceutical companies operating in India with a strong branded portfolio.
The company’s ability to maintain strong profitability while continuing shareholder payouts remains a major positive for long-term investors.
India’s pharmaceutical sector is expected to remain structurally strong over the coming years due to:
Companies with strong brands, healthy cash flows, and consistent dividend policies are likely to remain attractive during periods of broader market volatility.
Pfizer India delivered another stable operational performance in FY26 with revenue growth, strong operating cash generation, and a significant dividend announcement for shareholders.
While exceptional expenses impacted annual profitability, the company continues maintaining a strong balance sheet and stable business fundamentals within India’s defensive pharmaceutical sector.
The ₹75 dividend announcement further reinforces Pfizer India’s shareholder-friendly approach and highlights the resilience of branded pharmaceutical businesses amid uncertain global market conditions.
Pfizer India recommended a final dividend of ₹75 per equity share for FY26.
The company reported revenue from operations of ₹2,519.65 crore during FY26.
Pfizer India reported a net profit of ₹722.43 crore for FY26.
Profitability was impacted by exceptional charges related to personnel separation costs and labour code provisions.
Net cash generated from operating activities stood at ₹967.57 crore.
The dividend record date has been set as July 17, 2026.
Pharma companies generally benefit from stable demand, pricing power, and consistent cash flows even during economic uncertainty.
Chronic therapies, branded medicines, preventive healthcare, and rising healthcare awareness are major growth drivers.